See more : Chimney Co., Ltd. (3178.T) Income Statement Analysis – Financial Results
Complete financial analysis of Biotricity, Inc. (BTCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biotricity, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- TF Bank AB (publ) (TFBANK.ST) Income Statement Analysis – Financial Results
- Hubtown Limited (HUBTOWN.NS) Income Statement Analysis – Financial Results
- RBB Bancorp (RBB) Income Statement Analysis – Financial Results
- Click Holdings Limited (CLIK) Income Statement Analysis – Financial Results
- Yung Zip Chemical Ind. Co., Ltd. (4102.TWO) Income Statement Analysis – Financial Results
Biotricity, Inc. (BTCY)
About Biotricity, Inc.
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 9.64M | 7.65M | 3.38M | 1.42M | 398.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.71M | 4.20M | 3.08M | 2.11M | 931.95K | 338.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.36M | 5.44M | 4.57M | 1.27M | 485.77K | 59.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.27% | 56.46% | 59.74% | 37.60% | 34.26% | 15.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.57M | 3.23M | 2.74M | 2.06M | 1.36M | 1.31M | 1.76M | 1.14M | 1.14M | 23.20K | 53.60K |
| General & Administrative | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Other Expenses | 0.00 | -181.94K | -1.14M | -67.10K | 16.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.22K | -1.15K |
| Operating Expenses | 17.18M | 20.85M | 21.31M | 14.62M | 11.42M | 8.65M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Cost & Expenses | 20.89M | 25.05M | 24.39M | 16.74M | 12.35M | 8.99M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.19M | 2.58M | 10.57M | 2.48M | 92.42K | 0.00 | 879.42K | 1.18M | 59.88K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.95K | 346.26K | 68.34K | 347.12K | 148.76K | 8.58M | 7.72M | 5.94M | 9.05K | 810.00 | 1.15K |
| EBITDA | -8.90M | -15.40M | -18.02M | -13.35M | -10.93M | -8.59M | 0.00 | -5.94M | -5.12M | 0.00 | -89.92K |
| EBITDA Ratio | -73.75% | -161.69% | -233.65% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -15.59M | -17.88M | -13.42M | -10.91M | -8.59M | -7.72M | -5.94M | -5.13M | -90.41K | -91.07K |
| Operating Income Ratio | -73.18% | -161.75% | -233.68% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.27M | -3.25M | -12.39M | -2.78M | -136.26K | 0.00 | -900.00K | -1.87M | -55.85K | 7.00 | 0.00 |
| Income Before Tax | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Income Before Tax Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.40M | 9.43M | 2.07M | -39.41K | -171.86K | -6.84M | -4.76M | 50.82K | -810.00 | -1.15K |
| Net Income | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Net Income Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| EPS Diluted | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| Weighted Avg Shares Out | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
Biotricity Achieves Positive Free Cash Flow Milestone
First Time in the Company's History REDWOOD CITY, Calif. , Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB: BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced achieving positive...
Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript
Biotricity, Inc. (OTC:BTCY) Q2 2025 Earnings Conference Call November 15, 2024 4:30 PM ET Company Participants Dr. Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - Chief Financial Officer Conference Call Participants Kevin Dede - H.C. Wainwright Operator Greetings.
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter...
Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare...
Delisting of Securities of Gamer Pakistan Inc.; Biotricity, Inc.; Zalatoris II Acquisition Corp.; Warrantee Inc.; Spectaire Holdings, Inc.; Centogene N.V.; DZS Inc.; Corner Growth Acquisition Corp. 2; Collective Audience, Inc.; Grom Social Enterprises Inc.; Fintech Ecosystem Development Corp.; Edgio, Inc.; Kineta, Inc.; BurgerFi International Inc.; A SPAC II Acquisition Corp.; and African Agriculture Holdings Inc. from The Nasdaq Stock Market
NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Gamer Pakistan Inc. Gamer Pakistan Inc.'s securities were suspended on August 5, 2024, and have not traded on Nasdaq since that time.
Biotricity Provides Updated Guidance for Earlier than Expected Path to Profitability due to Growing Revenues and Improving Margins
The company has achieved EBIDTA positive on a go-forward cash basis REDWOOD CITY, CA / ACCESSWIRE / October 3, 2024 / Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company that is reshaping the landscape of the healthcare industry with state-of-the-art...
Biotricity Announces Inclusion as a Supplier to A Prominent Medical System That Services 21 States
REDWOOD CITY, CA / ACCESSWIRE / September 26, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting-edge remote monitoring and diagnostic solutions, announces its inclusion as a supplier to another major...
Biotricity Kicks off Another Pilot Program with a Major Hospital System that Services over 800K Individuals
REDWOOD CITY, CA / ACCESSWIRE / September 19, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting edge remote monitoring and diagnostic solutions, announces the launch of a new cardiac monitoring...
Biotricity Reports Continued Margin Improvement and Reduced Losses in its First Quarter Fiscal Year 2025
The Company shows continued progress towards cash-flow break even and profitability Recurring Technology Fee (SaaS) revenue - over 94% of total revenue with a 76% gross margin, which rose over 400 basis points and is expected to continue to trend...
LOBO EV and Nexalin Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday,...
Source: https://incomestatements.info
Category: Stock Reports